We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock

35 hedge funds and large institutions have $116M invested in Yarrow Bioscience, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

0% less ownership

Funds ownership: 0.02%0.02% (-0%)

8% less funds holding

Funds holding: 3835 (-3)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

80% less capital invested

Capital invested by funds: $579M → $116M (-$463M)

Holders
35
Holders Change
-3
Holders Change %
-7.89%
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
11
Increased
7
Reduced
5
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
VC
1
Vivo Capital
California
$32.6M
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$16.5M -$77.7K -2 -0.4%
VP
3
venBio Partners
California
$11.9M
NHAS
4
Novo Holdings A/S
Denmark
$11.7M +$816K +21 +6%
PA
5
Perceptive Advisors
New York
$10.1M -$3.85M -99 -22%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$9.08M
BBA
7
Baker Bros. Advisors
New York
$5.68M
BlackRock
8
BlackRock
New York
$3.68M -$38.9K -1 -0.8%
RSCM
9
Rock Springs Capital Management
Maryland
$2.68M
DCM
10
DAFNA Capital Management
California
$2.53M +$3.38M +87 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$2.13M +$661K +17 +30%
Millennium Management
12
Millennium Management
New York
$1.74M +$2.29M +59 New
JP Morgan Chase
13
JP Morgan Chase
New York
$1.04M +$155K +4 +13%
State Street
14
State Street
Massachusetts
$759K +$77.7K +2 +8%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$558K +$38.9K +1 +6%
Northern Trust
16
Northern Trust
Illinois
$548K
SSA
17
Schonfeld Strategic Advisors
New York
$406K +$544K +14 New
ARTA
18
A.R.T. Advisors
New York
$257K +$350K +9 New
First Manhattan
19
First Manhattan
New York
$248K +$311K +8 New
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$231K +$311K +8 New
Charles Schwab
21
Charles Schwab
California
$202K -$38.9K -1 -13%
CWM
22
Cornerstone Wealth Management
Missouri
$200K
Bank of New York Mellon
23
Bank of New York Mellon
New York
$170K +$38.9K +1 +20%
OAM
24
Oxford Asset Management
United Kingdom
$131K -$1.09M -28 -85%
Citadel Advisors
25
Citadel Advisors
Florida
$130K

YARW Hedge Fund Activity: Q2 2018 in Review

35 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q2 2018, worth a combined $116M — down 80% from $579M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of YARW and 11 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 7 added.

The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $3.38M. The largest seller was Deerfield Management, exiting entirely with an estimated $16M sold.

  • 35 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q2 2018, down from 38 in Q1 2018.
  • Funds reported $116M of Yarrow Bioscience, Inc. Common Stock stock for Q2 2018, down 80% quarter-over-quarter.
  • 11 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q2 2018 and 14 closed out, a net change of -3 holders.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q2 2018 was DAFNA Capital Management, an estimated $3.38M added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q2 2018 was Deerfield Management, an estimated $16M sold.

Based on aggregated 13F filings for Q2 2018.